{
    "clinical_study": {
        "@rank": "97317", 
        "acronym": "ESSENTIAL", 
        "arm_group": {
            "arm_group_label": "Red blood cell exchange for patients with sickle cell disease", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the performance of the Spectra Optia system red\n      blood cell exchange (RBCx) protocols (exchange and depletion/exchange) in study participants\n      with sickle cell disease."
        }, 
        "brief_title": "Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Sickle Cell Disease", 
        "condition_browse": {
            "mesh_term": "Anemia, Sickle Cell"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 12 years old\n\n          -  Enrolled in a program of regular RBCx to prevent symptoms/complications of sickle\n             cell disease (SCD) or Initiating a program of regular RBCx or Receiving RBCx as a\n             pre-surgical procedure.\n\n          -  Medically stable\n\n          -  Previous documentation of diagnosis by hemoglobin electrophoresis of a type of sickle\n             cell disorder requiring RBCx.\n\n          -  Sufficient vascular access to accommodate the RBCx procedure as determined by the\n             apheresis technician performing the procedure or phlebotomist responsible for\n             obtaining intravenous access.\n\n          -  Availability of sickle trait negative, leukoreduced, ABO, Rh (D) compatible,\n             unexpired replacement blood. See Glossary for definition of replacement blood.\n\n          -  Able to commit to the study follow-up schedule.\n\n          -  Agree to report adverse events (AEs) during the required reporting period.\n\n        Exclusion Criteria:\n\n          -  Inability to obtain informed consent/assent from patient, or permission from parent\n             or guardian.\n\n          -  Pregnancy (negative serum pregnancy test required for females of childbearing\n             potential).\n\n          -  Life expectancy is fewer than 30 days from time of procedure.\n\n          -  Incarcerated or a ward of the court.\n\n          -  Refusal of blood products.\n\n          -  Failure to comply with site standard requirements for cessation of medications (e.g.,\n             ACE inhibitors) that interfere with or increase risk of RBCx procedures.\n\n          -  History of drug or alcohol abuse that, in the opinion of the investigator, could\n             affect the ability of the patient to comply with the study requirements Inability to\n             comply with the protocol in the opinion of the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "73", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736657", 
            "org_study_id": "CTS-5001"
        }, 
        "intervention": {
            "arm_group_label": "Red blood cell exchange for patients with sickle cell disease", 
            "description": "The purpose of this study is to evaluate the performance of the Spectra Optia system.", 
            "intervention_name": "Red blood cell exchange for patients with sickle cell disease", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 22, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "Children's of Alabama"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "Children's Hospital and Research Center at Oakland"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado at Denver"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "Kosair Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins Medical"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.", 
        "overall_official": {
            "affiliation": "Children's Hospital and Research Center at Oakland", 
            "last_name": "Keith Quirolo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint will evaluate the mean ratio of the Actual Fraction of Cells Remaining (FCRa; as measured by Post-Procedure % HbS) to the Predicted Fraction of Cells Remaining (FCRp; as predicted by the Spectra Optia system FCR algorithm), in the Evaluable subject population.", 
            "measure": "Evaluate the mean ratio of FCRa to FCRp", 
            "safety_issue": "No", 
            "time_frame": "Six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Procedural Success of the Spectra Optia system in the Evaluable population", 
                "safety_issue": "No", 
                "time_frame": "Six months"
            }, 
            {
                "measure": "Spectra Optia system's ability to achieve the desired final hematocrit in the Evaluable population", 
                "safety_issue": "No", 
                "time_frame": "Six months"
            }, 
            {
                "measure": "Device-related serious adverse events (SAE) in the Full Analysis Set", 
                "safety_issue": "Yes", 
                "time_frame": "Six months"
            }
        ], 
        "source": "Terumo BCT", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Terumo BCT", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}